Ripyso Paed 75 mg and 50 mg Dispersible tablet
PDF Leaflet Revision Date: 26 July 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Indicated for pulmonary tuberculosis in children.
Dosage (summary)
Daily maximum: Rifampicin 15 mg/kg (up to 600 mg), Isoniazid 10 mg/kg (up to 300 mg).
Special Populations
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Safety in pregnancy and lactation not established; both drugs cross placenta and are excreted in breastmilk.
Key Drug Interactions
- Nevirapine
- Saquinavir/ritonavir
- Alcohol
- Corticosteroids
Contraindications
- Hypersensitivity to rifamycins or isoniazid
- Jaundice
- Hepatic impairment
- Renal impairment
- Diabetes mellitus
- Chronic alcoholism
- Convulsive disorders
- Porphyria
Common side effects
- Nausea
- Vomiting
- Diarrhoea
- Hepatitis
- Peripheral neuropathy
Counselling Points
- Take on an empty stomach
- Monitor for liver function
- Avoid alcohol
- May cause urine discoloration
Serious warnings
- Serious hepatotoxicity
- Anaphylaxis risk with intermittent therapy
Important Disclaimer
The Ripyso Paed 75 mg and 50 mg Dispersible tablet professional information leaflet below is the property of Macleods Pharmaceuticals Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
